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The cellular prion protein (PrPC) has been widely investigated ever since its conformational
isoform, the prion (or PrPSc), was identified as the etiological agent of prion disorders. The
high homology shared by the PrPC-encoding gene among mammals, its high turnover rate
and expression in every tissue strongly suggest that PrPC may possess key physiological
functions. Therefore, defining PrPC roles, properties and fate in the physiology of
mammalian cells would be fundamental to understand its pathological involvement in prion
diseases. Since the incidence of these neurodegenerative disorders is enhanced in aging,
understanding PrPC functions in this life phase may be of crucial importance. Indeed, a
large body of evidence suggests that PrPC plays a neuroprotective and antioxidant role.
Moreover, it has been suggested that PrPC is involved in Alzheimer disease, another
neurodegenerative pathology that develops predominantly in the aging population. In prion
diseases, PrPC function is likely lost upon protein aggregation occurring in the course of
the disease. Additionally, the aging process may alter PrPC biochemical properties, thus
influencing its propensity to convert into PrPSc. Both phenomena may contribute to the
disease development and progression. In Alzheimer disease, PrPC has a controversial
role because its presence seems to mediate β-amyloid toxicity, while its down-regulation
correlates with neuronal death. The role of PrPC in aging has been investigated from
different perspectives, often leading to contrasting results. The putative protein functions
in aging have been studied in relation to memory, behavior and myelin maintenance. In
aging mice, PrPC changes in subcellular localization and post-translational modifications
have been explored in an attempt to relate them to different protein roles and propensity
to convert into PrPSc. Here we provide an overview of the most relevant studies attempting
to delineate PrPC functions and fate in aging.
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INTRODUCTION
The conformational conversion of the cellular form of the prion
protein (PrPC) into a β-sheet enriched isoform denoted as prion
(PrPSc) is central in neurodegenerative pathologies collectively
know as prion diseases (Prusiner, 2001).
The PrPC is a sialoglycoprotein that is attached to the outer
leaflet of the plasma membrane via a C-terminal glycosylphos-
phatidylinositol (GPI) anchor (Stahl et al., 1990). In the cell PrPC
may be expressed in different glycosylated forms, corresponding
to the variable occupancy of the residues Asn180 and Asn196
(Haraguchi et al., 1989). While the C-terminal domain is folded
in ordered and distinctive secondary structures, the N-terminal
portion is flexible, unstructured and contains a unique octapep-
tide repeat (OR) region (Zahn et al., 2000). The OR confers PrPC
one of its most salient features, i.e., the ability to bind divalent
cations, prominently copper and to a lesser extent zinc, nickel,
iron, and manganese (Stockel et al., 1998; Jackson et al., 2001;
Singh et al., 2010; Arena et al., 2012). Indeed, at physiological
pH copper shows the highest binding affinity (Chattopadhyay
et al., 2005; Liu et al., 2011). The importance of copper binding
for PrPC function is reflected in the high OR structural homol-
ogy among different species (Hornshaw et al., 1995). Two of the
most investigated putative functions for PrPC are neuroprotection
and defense against oxidative stress, both relevant in neurodegen-
eration and cell aging (Vassallo and Herms, 2003; Roucou and
LeBlanc, 2005; Aguzzi et al., 2008). In agreement with these find-
ings, PrPC copper binding sites support the reduction of Cu2+
to Cu+, thus preventing reactive oxygen species (ROS) formation
(Liu et al., 2011).
Although contrasting results are likely due to the different
experimental protocols employed, PrPC is expressed in almost
all body organs and tissues, from embryonic to aging stages
(Fournier et al., 1998; Goldmann et al., 1999; Sales et al., 2002).
However, the expression levels are differently regulated according
to the age and tissue distribution. For instance, while PrPC shows
a high expression in the central nervous system (CNS), where it is
differently regulated during development and aging, it is present
at very low levels in the liver (Horiuchi et al., 1995;Moudjou et al.,
2001; Peralta et al., 2012). The broad homology conservation of
the PrPC-encoding gene among mammalian and avian species
(Hornshaw et al., 1995), the expression of the protein in many tis-
sues during the entire lifespan, and its high turnover rate strongly
indicate that PrPC possesses key physiological roles. However, the
definition of PrPC’s univocal function is still under debate.
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The PrPSc isoform can form protein aggregates, known as
prion deposits, often present as amyloid structures, which can
propagate and possibly cause cell death. Despite continuous
steps forward toward the definition of the conformational switch
mechanism, the trigger of the posttranslational remodeling event
is still obscure, especially in sporadic prion disorders. In the
inherited forms of prion diseases, a genetic mutation in the open-
reading frame of the gene leads to amino acid substitutions, which
in turn destabilizes the protein structure over time, promoting
PrPC to PrPSc conversion. In the infective forms, a preformed
PrPSc-aggregate triggers the conversion of endogenous PrPC. In
the sporadic forms of the disease, several unknown factors may
perturb the protein structure, thus favoring PrPSc formation
(Prusiner, 1991, 1994).
If a cause-effect relationship between prion deposits and cell
death does not always exist (Lasmezas et al., 1997), a probable
consequence of PrPC conversion into PrPSc is the loss or alteration
of its cellular function. Whether this impairment contributes
or not to disease development is still under debate. Moreover,
PrPC is also involved in Alzheimer disease (AD) (Kellett and
Hooper, 2009). Whether in AD PrPC mediates neuroprotection
or β-amyloid toxicity is still under investigation.
All these observations, together with the fact that the highest
incidence of prion disorders and AD is in the elderly popula-
tion, have renewed the interest of scientists in investigating of the
role of PrPC during aging. The two main topics under study have
been: (i) PrPC physiological functions in aging models, and (ii)
consequent changes in PrPC biochemical properties. The latter
may be triggered by the cellular aging process and may promote
prion aggregate formation. To date, studies into PrPC role in
aging are contrasting, mostly due to different animal/cellular sys-
tems employed and the lack of consistency in defining aging in
experimental models.
Here we provide a comprehensive overview of studies attempt-
ing to understand PrPC function and fate in aging and relate them
to the neurodegenerative processes.
AGING
In mammals, aging is defined as the accumulation of changes
in an individual over time and represents a multifaceted pro-
cess of social, psychological, and physical alterations (Bowen
and Atwood, 2004). Normal aging is associated with signifi-
cant cognitive declines, such as decreased speed of information
processing, working memory capacity, and long-term memory
function (Hedden and Gabrieli, 2004). However, changes that
occur in aging brains are less linked to chronological time than
it was thought in the past. For instance, individual brains may
grow old developing less alterations than others (Esiri, 2007).
The study of age-related changes in the human brain is chal-
lenging for two main reasons: (i) increasing improvement of
nutrition during the last century limits our ability to directly com-
pare human brain samples between generations; and (ii) most
elderly brains show some pathological hallmarks, thus complicat-
ing the distinction between “normal aging” and “disease” (Esiri,
2007). In the past, it was thought that the main cause of age-
related cognitive decline was massive neuron loss (Brody, 1955)
and deterioration of dendritic branches (Scheibel et al., 1976;
Scheibel, 1979). Now we know that alterations occurring in nor-
mal aging are more subtle and selective. In fact, it seems that most
age-linked behavioral impairments are due to region-specific
changes in dendritic morphology, cellular connectivity, calcium
dysregulation, gene expression or other factors that affect plastic-
ity and alter neuron network dynamics (Burke and Barnes, 2006).
A crucial factor for brain aging is the enormous requirement
that neurons have for oxidative metabolism required by energy
consumption. Neurons need extraordinary amounts of energy
because of: (i) the size and the ensuing energy-consumption
system of transport for molecules and organelles; and (ii) the
electrical activity for impulse transmission, implying ion gradient
maintenance. The high degree of oxidative metabolism generates
high amounts of ROS that damage proteins, nucleic acids and
lipids, thus interfering with normal cell metabolism and result-
ing, for instance, in altered gene expression and abnormal protein
generation (Esiri, 2007).
Mitochondrial efficiency decline, paralleled by oxidative stress,
which occurs with aging, is connected to alterations in calcium
homeostasis, in particular to higher calcium content in neuron
cytosol after excitatory stimulation. Indeed, glutamate activation
of N-methyl-D-aspartate (NMDA) receptors produces a tran-
sient elevation in intracellular calcium concentration, which is
increased in normal aging. Disruption in calcium homeostasis
predisposes aging neurons to more extended damage after stress
and eventually leads to cell death by apoptosis (Cowan et al., 2001;
Thibault et al., 2001; Esiri, 2007).
In this scenario, PrPC may possess different functions: (i) neu-
ron protection from oxidative stress through antioxidant activ-
ity, by sensing copper and/or free radical stimuli (Vassallo and
Herms, 2003); (ii) modulation of calcium entry through NMDA
receptor pore by inhibition of the channel activity (Cowan et al.,
2001; Lo et al., 2007); (iii) anti-apoptotic effect on Bax-mediated
cell death (Bounhar et al., 2006; Lo et al., 2007).
WHICH MOUSE AGE SHOULD BE CONSIDERED AS AN AGING MODEL?
For many reasons, researchers often use terms as aged or old mice
that may not be proper by definition. A wild-type mouse goes
through the following life phases (http://research.jax.org/faculty/
harrison/ger1vLifespan1.html) (Flurkey et al., 2007):
• Mature adult [3–6 months old (mo) mouse]: this period is the
reference for any age change; thesemice are fully developed, but
not senescent; after 6 months of age mice can show some age-
related changes, for instance females are retired from breeding
because litter size begins to diminish.
• Middle age (10–15 mo mouse): senescent changes can be
detected in some, but not all, biomarkers of aging; these mice
are generally used to determine if an age-related change is
progressive or occurs only in old age.
• Old (18–24 mo mouse, or older): senescent changes can be
detected in almost all biomarkers in all animals.
Taking into account these categories, few studies claiming the
use of old mice indeed employ a properly aged model. For the
purposes of this manuscript, this point has to be carefully taken
into account, especially in respect of studies on PrPC biochemical
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property changes in aging. On the other hand, studies on PrPC
knockout mice (also noted as Prnp0/0), when not performed on
old animals, as defined above, can nevertheless reveal progressive
age-related changes that start earlier because of PrPC absence. To
let the reader critically consider reported results and conclusions,
we will specify for each reviewed study the age of the animals used.
PrPC ROLE IN AGING
As previously mentioned, PrPC is highly conserved and expressed
among mammals, and it may play important physiological roles.
However, numerous efforts aimed at identifying PrPC func-
tion have harbored contrasting results. Most of the work has
focused on the nervous system, which is the organ with the
highest PrPC expression and the site of prion disease pathol-
ogy. Several results have linked PrPC to many cellular pro-
cesses, such as neuronal survival, neurite outgrowth, synapse
formation/maintenance/functionality, and myelinated fiber for-
mation/maintenance (Aguzzi et al., 2008). However, its expres-
sion in many other tissues indicates that PrPC has either many
different functions or a function compatible with diverse cellular
types.
A large body of evidence suggests that PrPC plays a role in
essential metal homeostasis, resulting in protection from oxida-
tive stress. An overlap between systems controlling essential metal
homeostasis and oxygen radical metabolism has been exten-
sively documented (Avery, 2001). For instance, many antioxidant
enzymes need metal ions as cofactors. PrPC has been associ-
ated with cellular systems that control redox balance and protect
against oxidative stress (Brown and Sassoon, 2002). Indeed, PrPC-
null models show: (i) increased neuronal sensitivity to oxidative
stress (Brown et al., 1997; Rachidi et al., 2003); (ii) alterations
of superoxide dismutase 1 (SOD1) activity due to impairments
in copper incorporation (Brown and Besinger, 1998; Kralovicova
et al., 2009); (iii) higher levels of lipids and protein oxidation
(Wong et al., 2001). Moreover, PrPC expression is increased by
heat shock, hypoxia, ischemia, hypoglycemia, stroke, and knock-
down of any SOD protein while shutting down PrPC increases
extracellular-SOD expression and SOD2 activity (Brown and
Besinger, 1998; Shyu et al., 2000, 2004, 2005; McLennan et al.,
2004; Mitsios et al., 2007; Kralovicova et al., 2009). Furthermore,
in vitro PrPC possesses SOD-like activity with a dismutation con-
stant rate similar to SOD2 (Brown et al., 1999, 2001; Cui et al.,
2003; Treiber et al., 2007). A possible link between SOD and PrPC
may be copper. Indeed, SOD activity depends on copper incor-
poration and probably involves Cu2+ reduction, characteristics
shared with PrPC (Brown et al., 2001). It should also be noted
that PrPC is cleaved at the end of the OR through the action of
ROS, a process termed β-cleavage. β-cleavage is considered an
early and critical event in the mechanism through which PrPC
protects cells against oxidative stress. If a PrP construct lacks the
OR, the protein will fail to undergo ROS-mediated β-cleavage,
as occurs with two mutant forms associated with prion diseases
(Watt et al., 2005).
PrPC ROLE IN BEHAVIOR AND LEARNING AS A FUNCTION OF AGE
Two main observations suggest that PrPC plays a role in behav-
ior and learning mechanisms in aging: (i) PrPC is predominantly
expressed in neurons, reaching the highest level in the hippocam-
pus (DeArmond et al., 1987; Benvegnu et al., 2010); (ii) PrPC
brain expression is increased in aging (Williams et al., 2004).
However, studies carried out on PrPC knockout mice have some-
times produced contrasting results, likely due to differences in
lines and age.
The behavioral characterization of the first PrPC knockout
(ZurichI) mouse generation was performed in 7 mo mice (Bueler
et al., 1992). At this age these mice cannot be considered aged.
Nevertheless, the latter study represents a good starting point
toward analyzing alterations triggered by PrPC ablation. In the
swim test and in the Y-maze, PrPC knockout mice did not reveal
learning impairments, although there were large individual dif-
ferences within test and control groups. In the two-way avoidance
test, in which animals have to avoid an electrical shock announced
by a light by running to the opposite chamber of the box, thus
involving also motorial ability, PrPC knockout mice showed a
slightly lower performance, but the great variability in each group
hid a possible significant difference. As Büeler and colleagues
state, these results should be carefully considered because of the
dissimilar loci surrounding Prnp0/0 and wild-type (Prnp+/+)
alleles, due to different genetic background.
However, a follow-up study using the same mouse line showed
that Prnp0/0 mouse aging-related behavior alterations could not
be ascribed to surrounding loci differences, but to PrPC ablation
itself (Coitinho et al., 2003). Differently from Büeler and col-
leagues data, here statistically significant results were obtained by
applying other behavioral tests and by increasing the animal age: 9
and 3 mo Prnp0/0 and Prnp+/+ mice were compared in regards to
fear-motivated learning, locomotor activity, exploratory behavior
and anxiety. Nine mo PrPC knockout mice showed impairments
in short- and long-term memory and exploratory activity. With
exception of the exploratory activity, 9 mo Prnp0/0 mouse perfor-
mances were recapitulated in 9 mo rats injected in the hippocam-
pus with anti-PrPC antibody, thus ruling out the involvement of
the surrounding loci in memory alterations in the aging PrPC
knockout line.
Another study concerning aging-related PrPC role in behav-
ior control was performed on 3 and 11 mo mice from three
lines (wild-type, Prnp0/0 and PrPC overexpressing Tga20 on a
Prnp0/0 genetic background) (Rial et al., 2009). Collectively the
data showed that PrPC overexpressing Tga20 mice were less sus-
ceptible to aging-caused alterations in locomotion, anxiety like
responses and short-term social recognition memory in com-
parison with Prnp+/+ and Prnp0/0 mice. On the contrary, PrPC
knockout mice resulted more susceptible to age-related decline in
comparison with wild-type mice. Biochemical analyses revealed
that Tga20mice have lower neuron caspase3 activation and serum
acetylcholinesterase levels, and higher synaptic density. In light
of these cognition-enhancing properties, Rial and colleagues sug-
gest in particular the interaction of PrPC with the stress-inducible
protein 1 as a target for pharmaceutical intervention to attenuate
age-related cognitive impairments.
More recent results confirmed age-dependent behavioral
abnormalities in ZurichI PrPC knockout mice (Schmitz et al.,
2014). The following alterations were reported: (i) poor native
nest building behavior in young (3 mo) and old (9 and 20 mo)
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PrPC knockout mice; (ii) higher latency in exploring a new envi-
ronment only in young but not in old PrPC knockout mice;
(iii) more pronounced drop in anxiety during aging in PrPC
knockout mice; (iv) decline in associative learning in old PrPC
knockout mice compared to age-matched wild-type. Schmitz and
colleagues wanted to relate the observed behavioral abnormal-
ities to neuron structural alterations in PrPC knockout mice.
They found PrPC-dependent alterations in cytoskeletal proteins
that are responsible for morphology, structure, and stability of
neurons, thus related to learning processes. Indeed, PrPC was pre-
viously reported to functionally interact with cytoskeletal proteins
(Dong et al., 2008; Malaga-Trillo et al., 2009).
Telling’s group performed a work on a slightly different line,
the ZurichI crossed with wild-type FVB animals (Nazor et al.,
2007). On the rotarod, Prnp0/0 on FVB background mice showed
an age-dependent motor behavior deficit in comparison to wild-
type, suggesting a function for PrPC in maintaining sensorimotor
coordination. This difference between wild-type and PrPC knock-
out mice was detected starting from 3 to 8 mo. Moreover, these
mice at 6 mo revealed vacuolation in different brain regions.
Although vacuolation has been rarely reported in PrPC knockout
mice, Telling and coworkers parallel their findings, concerning
both spongiosis and motor impairments, with results from a
transgenic murine model expressing the PrP mutation linked to
Gerstmann–Sträussler–Scheinker syndrome (GSS), thus suggest-
ing the loss of PrPC function as disease mechanism.
Another study was performed by Massimino and colleagues
using three groups of congenic mice: wild-type FVB, PrPC knock-
out on FVB background and Tg46 mice in which PrPC expres-
sion was rescued over a PrPC knockout background (Massimino
et al., 2013). While young (3 mo) PrPC knockout mice did not
show any alteration, aged (15–18 mo) animals revealed perturbed
behavioral pattern, in particular difficulties in adapting to new
situations and in locomotor activity, likely due to a depressive syn-
drome. The authors suggest that PrPC absence affects emotional
reactivity. The authors did not carry out histological analysis of
old Prnp0/0 mice, therefore, it is not known whether the PrPC
knockout colony employed showed the vacuolation phenotype
observed by Telling’s group studying the same mouse line. To
our knowledge, the result obtained by Telling’s and coworkers is
the only one showing vacuolation in Prnp0/0 mice. For instance,
Aguzzi and colleagues did not detect any morphological anomaly
in 14 mo ZurichI Prnp0/0 mice (Bremer et al., 2010).
Taken together, all these studies demonstrate that PrPC
absence affects learning, cognitive and behavioral skills in aged
mice. A possible cause of these alterations is the lack of PrPC-
mediated neuroprotection and reduction of oxidative stress, par-
ticularly important to preserve neuron functions in the aging
brain milieu.
PrPC ROLE IN MYELIN MAINTENANCE
Alterations occurring during both normal aging and neurodegen-
erative pathologies largely involve maintenance and regeneration
of myelin structure (Verdu et al., 2000; Peters, 2002; Bartzokis,
2011). Metal ions, in particular copper and iron, are necessary
for both myelin formation and maintenance (Skripuletz et al.,
2008; Benetti et al., 2010). Therefore, PrPC may influence myelin
by maintaining copper and iron homeostasis, pathways in which
PrPC has been involved (Pauly and Harris, 1998; Brown and
Harris, 2003; Rachidi et al., 2003; Miura et al., 2005; Singh et al.,
2009). By studying 14 mo (middle aged) mice, Aguzzi’s group
reported that PrPC knockout mouse sciatic nerve contains more
digestion chambers, i.e., macrophages ingesting myelin debris of
degenerating nerve fibers, compared to wild-typemice.Moreover,
they showed that PrPC expression on neuronal cells, but not on
Schwann’s cells, is fundamental to preserve myelin fibers and pre-
vent chronic demyelinating polyneuropathy (CDP) in the periph-
eral nervous system. This finding suggests that neuronal PrPC in
trans expression is required for a directional communication from
axons to Schwann cells (Bremer et al., 2010).
As suggested in a study from our group (Benvegnu et al., 2011),
PrPC may exert a direct role in myelin sheath formation and
structural preservation through its modulation of β-secretase 1
(BACE1) (Parkin et al., 2007). Results obtained in sciatic nerves
from 15 mo mice highlight that PrPC influences cleavage and
processing of neuregulins. Neuregulins are a class of proteins cru-
cial for myelin maintenance in the peripheral nervous system,
and their cleavage by BACE1 is necessary for signaling func-
tions. Hence, PrPC positively regulates neuregulin processing,
thus affecting their function in myelin homeostasis, maybe by
modulating BACE1 activity. Interestingly, in the previously men-
tioned work, Aguzzi’s group showed that CDP is prevented by
PrPC variants that are permissive for proteolytic amino-proximal
cleavage, but not by variants that do not undergo cleavage.
Indeed, all transgenic mice showing CDP lacked C1, i.e., the frag-
ment generated by α-cleavage, while all transgenic mice in which
the CDP was rescued produced high C1 levels. Hence, the cleav-
age of PrPC seems to be functional for its myelinotrophic role
(Bremer et al., 2010).
AGING-RELATED MODIFICATION OF PrPC BIOCHEMICAL
PROPERTIES
The most common occurrence of human prion diseases (about
80%) is sporadic. This means that a trigger of prion patholo-
gies may be neither a genetic mutation nor an infectious seed,
but most likely an unknown alteration that provokes the switch
from PrPC to PrPSc (Prusiner, 2001). The aging process itself
may modify PrPC biochemical properties, making the protein
more prone to convert into PrPSc. For instance, loss of glycosy-
lation in cell models favors PrPC acquisition of PrPSc-like features
(Lehmann and Harris, 1997). Indeed, glycans regulate PrPC fold-
ing, intracellular trafficking, localization and function on the
neuronal surface, thus their pattern modifications can be likely
linked to the disease development. PrPC biochemical properties
that may be altered by cellular changes occurring during the aging
process are: expression levels, post-translational modifications,
such as glycosylation and phosphorylation, as well as localiza-
tion in cellular domains, such as inside/outside membrane lipid
rafts.
As mentioned in a previous paragraph, analysis of both
parenchyma and microvessels revealed higher levels of both
glycosylated and unglycosylated PrPC in C57Bl/6J old (18
and 24 mo) mice (Williams et al., 2004). Concerning PrPC
diverse glycosylation isoforms, the three main bands appearing
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in one-dimensional immunoblots are commonly considered
corresponding to di-glycosylated (∼35 KDa), mono-glycosylated
(∼32KDa) and un-glycosylated (∼28KDa) (Collinge, 2001; Pan
et al., 2002). However, by applying a panel of monoclonal
antibodies, the presence of additional lower molecular weight
bands representing N-terminally truncated PrPC isoforms has
been shown (Pan et al., 2002). Moreover, two-dimensional
immunoblot analysis revealed in human brain more than 50
PrPC species which derive from several glycosylation and cleavage
combinations. Interestingly, accumulation of aberrant full-length
PrPC bound to immature N-linked glycans is indeed a com-
mon feature of prion disease (Pan et al., 2005a,b,c). Spurred
by these findings, Goh and coworkers investigated N-linked gly-
cans on PrPC during normal aging in mouse, providing the
first glycan profile of full-length and truncated PrPC isoforms
(Goh et al., 2007). The oldest mice they used were 15mo. First,
they found that different mouse lines (i.e., CD-1 and FVB)
have different PrPC metabolism resulting in isoform heterogene-
ity. In general, they showed that the truncated form of PrPC
undergoes a simplification in its glycosylation process during
aging, while the amount of complex oligosaccharides on the
full-length PrPC increases. This finding contrasts with what was
observed in aging compared to young cattle (Yoshioka et al.,
2010), but resembles what was previously detected in human
brains affected by prion disorders (Pan et al., 2005b). It has been
shown that PrPC glycosylation state may modulate affinity for
copper binding (Moudjou et al., 2007). In particular, the non-
glycosylated species showed stronger binding to divalent cations
(copper and cobalt) in vitro. Therefore, decreasing PrPC glycosy-
lation levels during aging may increase copper binding capacity,
thus improving PrPC antioxidant function. Interestingly, galac-
tose, which has been detected in this study on full-length PrPC
in aging, is also highly present on PrPSc (Safar et al., 1990).
Moreover, sialic acid content increases with aging on the trun-
cated PrPC but remains unchanged on the full-length PrPC. As
the authors observe, the presence of anionic residues may mod-
ulate PrPSc mobility, thus facilitating its propagation in prion
disorders.
As previously mentioned, aging can modify PrPC subcellu-
lar localization. Indeed, our group reported that PrPC moves
from detergent soluble membrane fractions to lipid rafts in aged
(20–21mo) mouse hippocampus (Agostini et al., 2013). No dif-
ferences in the total PrPC expression amount were detected, in
contrast with what had been previously reported by another
group that used the same mouse line and a very similar
age but lacked repeated samples, normalization and statisti-
cal analysis (Williams et al., 2004). Changes in the choles-
terol/sphingolipid ratio has been reported in normal brain
aging, and in degenerative disorders, such as AD (Martin
et al., 2010). As cholesterol and sphingolipids are the two
main components of lipid rafts, their relative amount influences
many cellular pathways, including protein localization (Martin
et al., 2008; Trovo et al., 2011). PrPC is a GPI-anchored pro-
tein, thus bound to lipid rafts and likely affected by aging-
related alterations in membrane composition. PrPC shift toward
lipid rafts triggered by changes in lipid composition was con-
firmed using model systems of lipid manipulation. Moreover,
decreasing sphingolipids, thus mimicking a juvenile condition,
reduced the formation of PrPSc in a cell line model. This
suggests that age-related changes influence PrPC localization
and ensuing propensity to PrPSc conversion (Agostini et al.,
2013).
PrPC AND AD
The most prevalent form of dementia is AD (Burns and Iliffe,
2009). Various factors are conducive to the risk of late-onset AD,
in particular old age, genetic factors, family history, a history of
head trauma, midlife hypertension, obesity, diabetes, and hyper-
cholesterolemia (Bendlin et al., 2010). AD is characterized by the
misprocessing of two proteins: intraneuronal tau and extracellu-
lar β-amyloid peptide (Aβ) (Querfurth and LaFerla, 2010). Aβ is
generated by the aberrant proteolytic processing of the amyloid
precursor protein by BACE1. Several studies have been performed
to understand if a toxic interaction between Aβ and PrP exists,
but the use of different in vitro or transgenic models has yielded
contrasting results (Schwarze-Eicker et al., 2005; Lauren et al.,
2009; Balducci et al., 2010; Calella et al., 2010; Chung et al.,
2010; Kessels et al., 2010; Morales et al., 2010; Ordonez-Gutierrez
et al., 2013). Thus, in this manuscript, we will consider only what
has been found by analyzing AD patient brains. Whitehouse and
colleagues found that PrPC levels are decreased in AD patient hip-
pocampus, normal aging hippocampus, and temporal lobe, but
not in AD patient temporal lobe (Whitehouse et al., 2010). With
exception of AD patient temporal lobe data, these results are in
contrast with what was reported by Saijo et al. (2011), but cor-
relate with the PrPC decrease detected in the cerebrospinal fluid
of patients affected by different neurological disorders includ-
ing AD (Meyne et al., 2009). Since PrPC inhibits BACE1 (Parkin
et al., 2007), PrPC level reduction may elevate Aβ production.
Therefore, Whitehouse and colleagues suggest that PrPC decrease
is not a secondary consequence, but a primary cause of AD
and, by occurring also in normal aging, increases the incidence
of AD in old individuals. Interestingly, individuals with muta-
tions in the PrP encoding gene generating a truncated form of
the protein developed clinical AD symptoms at relatively young
age (Kitamoto et al., 1993). In aging, BACE1 activity strongly
increases, thus enhancing Aβ production and the possibility of
deposit formation. The reduction of PrPC-mediated BACE1 inhi-
bition due to the decrease in PrPC levels may be a cause of the
enzyme activity elevation (Whitehouse et al., 2010). Additionally,
since PrPC is an antioxidant protein (Vassallo and Herms, 2003;
Aguzzi et al., 2008), its downregulation likely increases neuron
susceptibility to ROS, which rises in normal aging and in AD
(Halliwell, 2006; Zhu et al., 2007), hence contributing to disease
progression. However, a decrease in PrPC levels in AD does not
exclude that the residual protein mediates some Aβ toxic effects.
Besides, it has been recently reported that Aβ and PrPC do inter-
act specifically in AD patient brains (Dohler et al., 2014). This
result was obtained by means of a PrPC-Aβ binding assay and
size exclusion chromatography, and no binding was detected in
non-demented age-matched controls.
Taken together, these results indicate that PrPC may be
involved in AD. Therefore, its fate in aging is likely related to the
molecular mechanisms that induce neurodegeneration.
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CONCLUSIONS
As presented in this review, relatively few studies have been
carried out on the role of aging in the expression and regula-
tion of PrPC. Nevertheless, these experiments suggest that there
may be a correlation between the physiology of the cells in which
PrPC is present and its localization and processing during aging.
Particularly in the CNS, where it is abundantly expressed, PrPC
plays a prominent role as the precursor of PrPSc and thereby
dictates the amount and extension of the conversion and accumu-
lation process of prions. In aging, the physiology and the cellular
localization of the protein may change concomitantly to differ-
ent biochemical milieus in the cell membrane. Indeed, either
membrane composition, in particular lipid raft composition, or
additional protein complexes proximity to PrPC, may influence its
physiological functions. As indicated in the final paragraph, these
changes may have a general relevance for more common causes of
dementia such as AD. More work is necessary to define the pre-
cise role of PrPC in the progression of AD and perhaps in other
neurodegenerative diseases.
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